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Cancer cells can exploit the programmed death-1 (PD-1) immune checkpoint pathway to avoid immune surveillance by modulating T-lymphocyte activity. In part, this may occur through overexpression of PD-1 and PD-1 pathway ligands (PD-L1 and PD-L2) in the tumor microenvironment. PD-1 blockade has produced significant antitumor activity in solid tumors, and similar evidence has emerged in hematologic malignancies.
Methods
In this phase I, open-label, dose-escalation, cohort-expansion study, patients with relapsed or refractory B-cell lymphoma, T-cell lymphoma, and multiple myeloma received the anti-PD-1 monoclonal antibody nivolumab at doses of 1 or 3 mg/kg every 2 weeks. This study aimed to evaluate the safety and efficacy of nivolumab and to assess PD-L1/PD-L2 locus integrity and protein expression.
Results
Eighty-one patients were treated (follicular lymphoma, n = 10; diffuse large B-cell lymphoma, n = 11; other B-cell lymphomas, n = 10; mycosis fungoides, n = 13; peripheral T-cell lymphoma, n = 5; other T-cell lymphomas, n = 5; multiple myeloma, n = 27). Patients had received a median of three (range, one to 12) prior systemic treatments. Drug-related adverse events occurred in 51 (63%) patients, and most were grade 1 or 2. Objective response rates were 40%, 36%, 15%, and 40% among patients with follicular lymphoma, diffuse large B-cell lymphoma, mycosis fungoides, and peripheral T-cell lymphoma, respectively. Median time of follow-up observation was 66.6 weeks (range, 1.6 to
INTRODUCTION
The programmed death-1 (PD-1) pathway is an immune checkpoint to attenuate T-cell-mediated immune responses and may be exploited by tumors to avoid immune surveillance. 1 PD-1 and its ligands PD-L1 and PD-L2 are commonly expressed in tumor or neoplastic microenvironments, including epithelial malignancies, classic Hodgkin lymphoma (HL), and non-Hodgkin lymphoma (NHL), although the expression of PD-L1 seems to vary significantly among lymphoma subtypes. [1] [2] [3] There is more evidence for the role of PD-L1 in follicular lymphoma (FL), 4 but its role in other types of NHL has not been as clearly described. 3 Tumor cell expression of PD-L1 and PD-L2 can be upregulated due to genetic alterations of the 9p24.1 locus. [5] [6] [7] This is particularly true in HL, where amplification of 9p24.1 is frequently observed and is associated with positive staining for the ligands. 8 Inflammatory signaling facilitates PD-1 ligand overexpression on multiple immune and nonimmune cell types. 1 Multiple myeloma (MM) plasma cells exposed to inflammatory mediators, such as interferon-gamma and Toll-like receptor ligands, demonstrate increased expression of PD-L1; however, upregulation is not present in cells from patients with monoclonal gammopathy of uncertain significance.
9 PD-L1 interaction with PD-1 on tumor-infiltrating lymphocytes limits T-cell proliferation and cytotoxic functions. 10 The role of PD-L2 is less clear. Immune blockade of the PD-1/PD-L1 interaction by monoclonal antibodies can restore the antitumor activity of cytotoxic T cells.
11 PD-1-blocking antibodies (nivolumab and pembrolizumab) produced durable objective responses and improved overall survival (OS) in patients with solid tumors [12] [13] [14] [15] and hematologic malignancies, including HL. 8 NHL and MM are characterized by the neoplastic transformation and proliferation of normal lymphocytes and plasma cells, respectively. Patients with these diseases who experience a relapse after initial treatment or autologous stem cell transplantation (SCT) generally have a poor prognosis. Nivolumab (OPDIVO; Bristol-Myers Squibb, Princeton, NJ) is a fully human immunoglobulin G4 monoclonal antibody that targets the membrane PD-1 receptor on T cells and potentiates T-cell activity. This study evaluated the safety of nivolumab in patients with various hematologic malignancies. The integrity of the PD-L1 and PD-L2 loci and the expression of PD-L1 and PD-L2 proteins were also examined among a subset of patients with biopsy tissue available for analyses.
METHODS

Patients
This study was conducted in accordance with International Conference on Harmonisation Good Clinical Practice guidelines 16 and approved by the institutional review board of an independent ethics committee at each center. All patients provided written informed consent before enrollment on the basis of the ethical principles outlined in the Declaration of Helsinki.
17 For this phase I, open-label, dose-escalation, cohort-expansion study, patients with relapsed or refractory HL, NHL, and MM were eligible if they were age 18 years or older, had an Eastern Cooperative Oncology Group performance status of 0 or 1 with detectable or measurable disease, and had received at least one prior chemotherapy regimen. Patients with CNS involvement, concomitant secondary malignancies, active autoimmune disease, prior organ allograft or allogeneic SCT, prior treatment with immune checkpoint antibodies or concurrent treatment with receptor activator of nuclear factorkB ligand inhibitors were excluded. Results for the patients with HL have been reported separately. 8 
Treatment and Monitoring
During the dose-escalation portion of the study, eligible patients were treated with nivolumab 1 or 3 mg/kg administered as a 1-h infusion at weeks 1 and 4 and then every 2 weeks for up to 2 years, unless patients experienced disease progression or excessive toxicity or achieved a complete response (CR). Patients who discontinued treatment with ongoing response or stable disease (SD) could be retreated with nivolumab for confirmed disease progression that occurred within 1 year. The dose for the cohort expansion was selected on the basis of the safety determination from the dose-escalation portion of the trial. Because the maximum tolerated dose of nivolumab was not reached at the highest protocolspecified dose, patients in the cohort expansion were treated with nivolumab 3 mg/kg.
The primary objective of the study was safety. Secondary objectives included evaluation of antitumor activity and detection of alterations of the PD-L1 (CD274) and PD-L2 (CD273; PDCD1LG2) loci and protein expression of the encoded ligands. Safety outcomes were evaluated by assessment of adverse events (AEs) throughout the study and for 100 days after the last dose was administered. AEs were categorized in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4). 18 The safety evaluation included assessment of inflammatory AEs, such as pneumonitis, colitis, hypophysitis, thyroiditis, and skin disorders. These immune-mediated AEs are consistent with the mechanism of action of nivolumab and are known to occur with immune checkpoint inhibitors. Antitumor efficacy was assessed by tabulations of best overall response and analyses of objective response rate (ORR), duration of response (DOR), and progression-free survival.
Biomarker Assessment
Before initiating treatment with nivolumab, biopsies were performed to evaluate the tumor cells and immune-infiltrating cells for expression of immune-modulating proteins, including PD-L1 and PD-L2. Pretreatment bone marrow biopsies were mandatory for all patients and could be used as the baseline sample for biomarker assessment.
Fluorescent in situ hybridization (FISH) was performed on lymphoma tissue sections to analyze PD-L1 and PD-L2 loci as previously described. 8 The bacterial artificial chromosome probes (Children's Hospital of Oakland Research Institute, Oakland, CA) RP11-599H2O, which maps to 9p24.1 and includes CD274 (encoding PD-L1, labeled with Spectrum Orange [Abbott Molecular, Abbott Park, IL]), and RP11-635N21, which also maps to 9p24.1 and includes PDCD1LG2 (encoding PD-L2, labeled with Spectrum Green [Abbott Molecular]), were cohybridized. A control centromeric probe (Spectrum Aqua-labeled CEP9 [Abbott Molecular]) was hybridized according to the manufacturer's recommendations. 8 Immunohistochemical (IHC) staining was performed by means of an automated staining system (BOND-III; Leica Biosystems, Buffalo Grove, IL) by using a double-staining technique for PD-L1 (405.9A11) 19 and PAX5 (24/Pax-5; BD Biosciences, Franklin Lakes, NJ), and for PD-L2 (366C.9E5) 7 and phosphorylated signal transducer and activator of transcription (STAT) 3 (D3A7; Cell Signaling Technology, Beverly, MA). 8 IHC staining was reviewed and scored by a hematopathologist who collected the following data: percentage of malignant cells with positive staining (0% to 100%), intensity of staining of malignant and nonmalignant cells (0 = no staining, 1+ = weak/equivocal staining, 2+ = moderate staining, and 3+ = strong staining), and primary subcellular localization of positive staining (nuclear, cytoplasmic, or cell membrane). Previously published criteria for categorizing cases as positive for PD-L1 or PD-L2 expression in malignant cells were used. Malignant cells needed to exhibit 2+ or 3+ membrane staining in $ 5% of malignant cells for PD-L1 and 2+ or 3+ cytoplasmic or membrane staining in $ 5% of malignant cells for PD-L2. For the tumor microenvironment, $ 20% of nonmalignant cells needed to exhibit positive staining for PD-L1 or PD-L2 to be categorized as positive. 1, 7, 8 Statistical Analysis
All patients with NHL and MM who received at least one dose of nivolumab monotherapy were included in the safety and antitumor activity analysis. AEs were coded by using the Medical Dictionary for Regulatory Activities (version 17.0) and tabulated by system organ class and preferred term. The causal relationship between study medication and AEs was determined by the investigator at each site.
Efficacy assessments of individual best objective response were performed by the principal investigator at each site who used the revised Response Criteria for Malignant Lymphoma for patients with NHL, 20 the International Myeloma Working Group Uniform Response Criteria for patients with MM, 21 and the Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary syndrome 22 for patients with cutaneous T-cell lymphoma (CTCL). The ORR was the proportion of patients with a CR or a partial response (PR) as the best overall response. Median www.jco.org DOR, progression-free survival, and OS were estimated by Kaplan-Meier methodology.
RESULTS
Patients
Eighty-one patients with NHL or MM began treatment with nivolumab monotherapy between August 2012 and April 2015 when the database was locked for an interim analysis. One patient with chronic myelogenous leukemia was enrolled, and safety results for that patient are included in this analysis. Patients' baseline characteristics are shown in Table 1 . The 27 patients with MM had a median age of 63 years (range, 32 to 81 years). Median ages for 31 patients with B-cell lymphomas and 23 patients with T-cell lymphomas were 65 years (range, 23 to 74 years) and 61 years (range, 30 to 81 years), respectively. In the B-cell lymphoma group, 11 patients had DLBCL; 10 had FL; and 10 had other B-cell lymphomas, including mantle cell (n = 4), small lymphocytic (n = 2), primary mediastinal B cell (n = 2), marginal zone (n = 1), and B-cell NHL not otherwise specified (n = 1). The T-cell lymphoma group included 13 patients with mycosis fungoides (MF), five with peripheral T-cell lymphoma (PTCL), two with Sézary syndrome CTCL, and three with other non-CTCL. The median number of prior systemic treatment regimens in all patients was three (range, one to 12). Of patients with MM, DLBCL, T-cell lymphoma, and FL, 96%, 91%, 87%, and 70%, respectively, had received two or more prior systemic treatment regimens and 56%, 18%, 9%, and 20%, respectively, had a history of autologous SCT. Of 27 patients with MM, 24 experienced disease progression after prior immunomodulator and proteasome inhibitor therapy.
Safety
Seventy-nine (96%) patients experienced at least one AE. Drug-related AEs of any grade were reported in 53 (65%) patients (Table 2 ). Fifteen (18%) patients had grade 3 drugrelated AEs, two had grade 4 AEs, and one had a grade 5 AE. Immune-mediated AEs, potentially related to enhancements in immune response in the form of T-cell activation and proliferation, occurred in 28 (34%) patients and were predominantly grade 1 or 2. In 13 (46%) patients, the immune-mediated AEs resolved without treatment or interruption of nivolumab. Fifteen patients required treatment of immune-mediated AEs; of these, five had to discontinue nivolumab. With the exclusion of one patient whose AE outcome was unknown, immune-mediated AEs resolved spontaneously or after protocol-specified treatment in 82% of patients. Overall, 12 (15%) patients discontinued treatment because of drug-related AEs, including one episode each of grade 1 myositis and conjunctivitis; grade 2 enteritis www.jco.org and pneumonitis; grade 3 pneumonitis, stomatitis, neutropenia, diplopia, creatine phosphokinase increase, and rash; and grade 4 pneumonitis, pustular rash, and sepsis.
Fatal pneumonitis occurred in one patient, a 51-year-old woman with small lymphocytic B-cell lymphoma. She had nine prior systemic treatment regimens, including rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, bendamustine, ibritumomab tiuxetan radioimmunotherapy, panobinostat, ofatumumab, everolimus, and pentostatin. Active conditions at enrollment were exercise-induced asthma, tobacco use, chronic bronchitis, and sinusitis. Pretreatment symptoms included a chronic dry cough. Approximately 2 weeks after the first dose of nivolumab 3 mg/kg, pneumonitis developed. Despite treatment with corticosteroids and anti-infective medications, the patient experienced progressive deterioration complicated by respiratory failure and died 19 days after receiving one dose of nivolumab 6 days after pneumonitis onset.
Of the remaining eight patients with drug-related pneumonitis, two discontinued nivolumab due to pneumonitis (grade 2, n = 1; grade 3, n = 1). For five patients who continued nivolumab, pneumonitis (grade 1, n = 3; grade 2, n = 2) resolved in , 40 days without treatment or with corticosteroids. For one patient, grade 1 pneumonitis resolved with antibiotic and corticosteroid treatment but required . 40 days for resolution. None of the patients with drug-related pneumonitis had prior gemcitabine treatment; however, one patient received radiation to the right-side mediastinum and superior vena cava approximately 1 month before onset of grade 2 pneumonitis.
Clinical Outcomes
Among the 10 patients with FL and 11 patients with DLBCL, the ORRs were 40% (CR, n = 1; PR, n = 3) and 36% (CR, n = 2; PR, n = 2), respectively (Table 3 ; Figs 1A and 1B) . Objective responses were not observed among the 10 patients with other B-cell lymphomas. With a median observation time of 91.4 weeks for FL, three of four patients have had ongoing responses (all four continue to be followed); individual response durations were 81.6+ weeks for the patient with a CR and 27.1+, 28.1+, and 32.1+ weeks for the patients with PRs. The median follow-up duration for patients with DLBCL was 22.7 weeks; one of four patients in this group has had an ongoing response, and two continue to be followed. Individual response durations for the patients with CRs were 6.0 and 77.3+ weeks. For the patients with PRs, individual response durations were 12.1+ and 22.1 weeks. Sixteen patients with B-cell lymphoma had SD, with a median duration of 23.1 weeks (range, 6.9 to 44.0+ weeks).
Among the patients with T-cell lymphomas (n = 23), the response rate was 17% (PR, n = 4; Table 3 ; Figs 1C and 1D ). Responses occurred for two patients with MF and two patients with PTCL. With median follow-up times of 42.9 and 44.0 weeks for MF and PTCL, respectively, responses are ongoing for both patients with MF, with response durations of 24.3+ and 50.0+ weeks. Response is also ongoing for one of the patients with PTCL. Response durations for the two patients with PTCL were 10.6 and 78.6+ weeks. The median duration of SD was 11.0 weeks (range, 7.1 to 42.9+ weeks) for 10 patients with T-cell lymphomas.
The median follow-up duration for patients with MM was 65.6 weeks (range, 1.6 to 126 weeks). SD was the best response for 17 (63%) patients with MM, which lasted a median of 11.4 weeks (range, 3.1 to 46.1 weeks). A patient with MM achieved a best response of SD and then had an increase in k:l free light chain ratio and a rib plasmacytoma that became increasingly symptomatic. There was a month-long interruption of nivolumab while the patient underwent radiation for the rib lesion. After completion of radiation, nivolumab was restarted for 2 months then discontinued because the patient had been treated for approximately 2 years and was assessed as having a CR on the basis of the rib plasmacytoma having become asymptomatic. The patient is alive and has been in remission approximately 14 months since discontinuation of nivolumab treatment.
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Biomarker Assessment
Genetic alterations within the 9p24 locus detected by FISH were present in three of 27 patients from whom samples were obtained for analyses. FISH analysis of the biopsy sample MF #1 revealed an abnormal split signal for probes targeting PD-L1 and PD-L2 consistent with a breakpoint that maps 39 of the PD-L1 locus and 59 of the PD-L2 transcriptional start site on one of three copies of chromosome 9 (Fig 2; Appendix Table A1 , online only). IHC staining for PD-L2 revealed intense (3+) and membranous protein expression in 70% of malignant cells (Fig 2; Appendix Table A1 ). Positive nuclear staining for phosphorylated STAT3 consistent with active Janus kinase-STATsignaling in the malignant cells was also observed (Fig 2) . In contrast, IHC for PD-L1 revealed scattered positive staining in , 20% of nonmalignant cells and virtually no staining of malignant cells (Fig 2; Appendix Table A1 ). The morphologic features were consistent with large-cell transformation of MF. The patient achieved a PR for 47 weeks but discontinued therapy due to toxicity.
Two patients with DLBCL exhibited low-level polysomy of PD-L1/PD-L2. One had a best response of PR. The other patient had moderate intensity (2+) PD-L1 expression in a cell membranous pattern in 2% of malignant cells and had a best response of SD.
IHC analyses for PD-L1 and PD-L2 were largely negative in the malignant cells of the remaining cases, which lacked genetic alterations of PD-L1 and PD-L2 (Appendix Table A1 ). One of the B-cell lymphomas not otherwise specified exhibited PD-L2 expression (2+) in 20% of malignant cells, and one MF (MF #2) had PD-L1 expression (2+) in 20% of malignant cells (Appendix Table A1 ). In most cases, including certain FLs (Fig 3; Appendix Table A1 ), IHC staining revealed PD-L1 and, to a lesser extent, PD-L2 expression in variable percentages of nonmalignant immune cells within the tumor microenvironment (data not shown).
DISCUSSION
In patients with advanced hematologic malignancies, nivolumab had a safety profile similar to that seen in studies that involved patients with solid tumors 12 and HL. 8 The majority of drug-related AEs were grade 1 or 2, and the incidence of severe or life-threatening drug-related AEs was low across the various disease cohorts. Pneumonitis was observed in a small proportion of patients; most cases were grade 1 or 2 and were uniformly distributed across the spectrum of tumors in the study.
Nivolumab therapy resulted in ORRs of 36% and 40% among patients with DLBCL and FL, respectively. With continued nivolumab therapy, the depth of objective responses may improve as demonstrated by one patient with DLBCL with an initial PR (at 16 weeks) that converted to a CR (at 72 weeks) with extended treatment. Response durations exceeded 1 year for two (one each with FL and DLBCL) of three patients who achieved a CR and $ 6 months for patients with FL who achieved a PR.
Although less frequent than in B-cell lymphomas, durable objective responses were also seen in some PTCLs and CTCLs-diseases that are resistant to most standard chemotherapies. Thus, meaningful clinical activity was seen in both B-cell and T-cell lymphoma subtypes.
Tumor regression responses were not seen among patients with MM in this study, with the exception of one CR occurring after local radiation therapy, which suggests a possible abscopal effect. 23 The reason for the lack of objective responses in MM, compared with other tumors, is unclear and may relate to the immunosuppressive nature of the MM tumor microenvironment. 24 As previously reported, immunotherapy with ipilimumab produced objective responses in two (11%) of 18 patients (DLBCL, n = 1; FL, n = 1) with relapsed/refractory NHL. 25 Studies that involved combinations of nivolumab with rituximab, ipilimumab, and other immuno-oncology therapies are ongoing to determine whether response rates and DOR achieved with nivolumab monotherapy can be improved, particularly in these B-cell lymphoma subtypes.
Genetic alterations of PD-L1 and PD-L2 were rare among the NHLs evaluated in this study-a stark contrast to the frequent 9p24.1 alterations in HLs. 8 Among the evaluated NHLs, the most significant finding was a chromosomal rearrangement that involved PD-L2 and associated high-level PD-L2 protein expression in malignant cells of a transformed MF (MF #1; Appendix Table A1 ). PD-L1 and, to a lesser extent, PD-L2 proteins were expressed by nonmalignant cells within the tumor microenvironment in NHLs, including certain FLs. These data highlight the likely differences in the frequency of 9p24.1 alterations and associated expression of the PD-1 ligands in specific lymphoid malignancies. The roles of these biomarkers as predictors of response to nivolumab are under current evaluation in phase II trials of DLBCL and FL.
In conclusion, PD-1 blockade with nivolumab is associated with a favorable safety profile and objective responses in patients with various types of NHL. Accordingly, phase II trials with nivolumab are under way in patients with relapsed or refractory FL and DLBCL. These studies and future combination trials will help to define the role of PD-1 blockade in hematologic malignancies.
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